CORT News and Press, Corcept Therapeutics Incorporated From 09/29/23

2023-09-29 09:59:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...

2023-09-29 09:58:19 ET More on Corcept Therapeutics Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade) Corcept Therapeutics Incorporated (CORT) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Corcept Therapeutics ...

Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) traded at a new 52-week high today and are currently trading at $31.67. So far today, approximately 67,134 shares have been exchanged, as compared to an average 30-day volume of 574.18k shares. Corcept Therapeutics Incorporated discov...

2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...

2023-08-07 15:40:00 ET Summary After making a new 2023 high on Monday, the market sold off for the next four days. The best performer last week was Volatility, as investors were concerned by the Fitch downgrade. The market made another new high for 2023 on Monday. For the rest...

2023-08-02 22:37:07 ET Corcept Therapeutics Incorporated (CORT) Q2 2023 Earnings Conference Call Aug 2, 2023 5:00 PM ET Company Participants Joseph Belanoff - Chief Executive Officer, President and Director Atabak Mokari - Chief Financial Officer Charlie Robb - C...

2023-08-02 16:52:56 ET Corcept Therapeutics press release ( NASDAQ: CORT ): Q2 GAAP EPS of $0.25 beats by $0.10 . Revenue of $117.7M (+13.8% Y/Y) beats by $8.1M . Increase in 2023 revenue guidance to $455 - $470 million, from $435 - $455 million For furth...

Phase 1b study demonstrates that miricorilant, a selective cortisol modulator, effectively reduces liver fat, improves liver health and key metabolic and lipid measures and is well-tolerated Corcept will initiate a Phase 2b study in the fourth quarter MENLO PARK, Calif., July 17...

Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared to nab-paclitaxel monotherapy Confirmatory Phase 3 ROSELLA trial underway, with planned enrollment of 360 patients i...

2023-06-08 08:33:03 ET Summary Corcept Therapeutics' stock is trading back at FY'22 range after a snapback rally leading into Q2 FY'23. The company is allocating capital to its clinical programs, but returns on these investments haven't beat the hurdle to date, leading to economic...